Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome

European Journal of Endocrinology

Volumn 154, Issue 3, 2006, Pages 433-440

  Kim, Sin Gon ^b   Ryu, Ohk Hyun ^b   Kim, Hee Young ^b   Lee, Kye Won ^b   Seo, Ji A ^b   Kim, Nan Hee ^b   Choi, Kyung Mook ^b   Lee, Juneyoung ^a   Baik, Sei Hyun ^b   Choi, Dong Seop ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University Ansan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; RESISTIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; ORAL GLUCOSE TOLERANCE TEST; PRETEST POSTTEST DESIGN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 33645225344     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02100     Document Type: Article

References (39)

1. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 47 507-514.
2. Marx N, Duez H, Fruchart JC & Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation Research 2004 94 1168-1178.
3. Marx N & Hombach V. Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells (in German). Zeitschrift für Kardiologie 2001 90 470-477.
4. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA & Law RE. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Journal of Cardiovascular Pharmacology 1999 33 798-806.
5. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H & Nakao K. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 26 2493-2499.
6. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J & Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001 86 3452-3456.
7. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U & Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279-1289.
8. Wang TD, Chen WJ, Lin JW, Chen MF & Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. American Journal of Cardiology 2004 93 362-365.
9. Sidhu JS, Kaposzta Z, Markus HS & Kaski JC. Effect of rosiglitazone on common carotid intimamedia thickness progression in coronary artery disease patients without diabetes mellitus. Arteriosclerosis Thrombosis and Vascular Biology 2004 24 930-934.
10. Blacher J, Asmar R, Djane S, London GM & Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999 33 1111-1117.
11. Amar J, Ruidavets JB, Chamontin B, Drouet L & Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. Journal of Hypertension 2001 19 381-387.
12. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. Journal of Hypertension 1999 17 (Suppl 5) S41-S44.
13. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P & Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 37 1236-1241.
14. Kershaw EE & Flier JS. Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology and Metabolism 2004 89 2548-2556.
15. Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, Froguel P, Nagai R & Kadowaki T. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Current Drug Targets-Immune, Endocrine & Metabolic Disorders 2003 3 243-254.
16. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB & Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association 2004 291 1730-1737.
17. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY & Chuang LM. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002 25 376-380.
18. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004 27 S15-S35.
19. Malik S, Wong ND, Franklin SS, Kamath TV, L'italien GJ, Pio JR & Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004 110 1245-1250.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical Asociation 2001 285 2486-2497.
21. World Health Organisation. The Asia-Pacific perspective refining obesity and its treatment. ITOF, 2000.
22. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK & Park KS. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2004 89 150-156.
23. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S & Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertension Research 2002 25 359-364.
24. Kubo T, Miyata M, Minagoe S, Setoyama S, Maruyama I & Tei C. A simple oscillometric technique for determining new indices of arterial distensibility. Hypertension Research 2002 25 351-358.
25. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M & Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004 173 13-18.
26. Koji Y, Tomiyama H, Ichihashi H, Nagae T, Tanaka N, Takazawa K, Ishimaru S & Yamashina A. Comparison of ankle-brachial pressure index and pulse wave velocity as markers of the presence of coronary artery disease in subjects with a high risk of atherosclerotic cardiovascular disease. American Journal of Cardiology 2004 94 868-872.
27. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K & Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005 91 589-594.
28. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R & Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000 43 278-284.
29. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK & Hsueh WA. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. Journal of Clinical Investigation 1995 96 354-360.
30. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Current Atherosclerosis Report 2000 2 327-335.
31. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W & Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arteriosclerosis Thrombosis and Vascular Biology 2005 25 1804-1809.
32. Raji A, Seely EW, Bekins SA, Williams GH & Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003 26 172-178.
33. Osei K, Gaillard T, Kaplow J, Bullock M & Schuster D. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 2004 53 1552-1557.
34. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA & Smith U. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 2005 48 96-104.
35. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X, Hernandez G, Gomis R & Conget I. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabetic Medicine 2003 20 743-745.
36. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS & Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001 409 307-312.
37. Banerjee RR & Lazar MA. Resistin: molecular history and prognosis. Journal of Molecular Medicine 2003 81 218-226.
38. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA & Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005 111 932-939.
39. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T & Defronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. International Journal of Obesity Related Metabolic Disorders 2004 28 783-789.